The content on this site is intended for healthcare professionals only
A novel strategy in treating endocrine resistance using combination therapy
Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast cancer
Bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer
Bevacizumab plus docetaxel compared with placebo plus docetaxel for locally recurrent or metastatic breast cancer
Exemestane vs tamoxifen followed by exemestane
Using biology of tumours to predict effective therapies
Translation of endocrine systemic treatment
New paradigms in tumour immunotherapy
Early breast cancer trials
Causes and prevention of breast cancer
Applying new proteomic technologies to improve patient management
Sentinel lymph node biopsy
